Psilocybin Microdosing on Cognition, Mood and Quality of Life
NCT07449351, Early phase 1, Not yet recruiting, Yale University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Psilocybin Microdosing on Cognition, Mood and Quality of Life | ClinicalTrials.gov |
| NCT number | NCT07449351 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Early phase 1 | ClinicalTrials.gov |
| Enrollment | 20 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Yale University | ClinicalTrials.gov |
| Conditions | Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI | ClinicalTrials.gov |
| Interventions | Psliocybin, Placebo | ClinicalTrials.gov |
| First posted | 2026-03-04 | ClinicalTrials.gov |
| Last updated | 2026-09-24 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | The Complex Working Memory Span (CWMS) Task- fMRI measure | From enrollment to end of treatment at 8 weeks. | CWMS Task assesses immediate plus delayed recall and working memory by assessing working memory capacity by presenting a list of stimuli to be recalled while simultaneously performing a secondary task. This task uses a fully crossed design which includes both same-domain CWMS conditions (e.g. verbal storage combined with verbal processing) as well as cross-domain CWMS conditions (e.g., verbal storage combined with spatial processing). BOLD signal Infrontal lobe. | ClinicalTrials.gov |
| Primary | NEO-Five-Factor-Inventory (NEO-FFI) | From enrollment to end of treatment at 8 weeks. | The NEO-FFI is a self-description questionnaire with 60 items for the measurement of the "big five": neuroticism, extraversion, openness, agreeableness, and consciousness. It uses a 5-point Likert scale ranging from "completely disagree" to "fully agree. | ClinicalTrials.gov |
| Primary | Beck Depression Inventory | From enrollment to end of treatment at 8 weeks. | This scale has a total of 21 items. Each item is scored from 0-3 points, and the total score ranges from 0-63 points. The higher the score, the higher the degree of depression. | ClinicalTrials.gov |
| Primary | Beck Anxiety Inventory | From enrollment to end of treatment at 8 weeks. | Beck Anxiety Inventory is a 21-item self-reported questionnaire which measures the existenceand severity of symptoms of anxiety. Each of the 21 items on BAI tool represents an anxiety symptom. A total score of 0 - 7 is interpreted as a "Minimal" level of anxiety; 8 - 15 as "Mild"; 16 - 25 as "Moderate", and 26 - 63 as "Severe". | ClinicalTrials.gov |
| Primary | Harvard Flourishing Measure | From enrollment to end of treatment at 8 weeks. | 12 questions, rating from 0 to 10 per question, sum score to calculate the 'flourish measure' will be used. | ClinicalTrials.gov |
| Primary | NIH Toolbox Cognitive Battery | From enrollment to end of treatment at 8 weeks. | Cognitive function will be assessed using the NIH Toolbox Cognition Battery, administered on an iPad. | ClinicalTrials.gov |
| Primary | Ecological Momentary Assessments (EMAs) w/ MindLamp | From enrollment to end of treatment at 8 weeks. | Once-daily questions (EMAs) about mood and sleep will be sent via the MindLamp smartphone app. | ClinicalTrials.gov |
| Primary | Switching Stroop Test | From enrollment to end of treatment at 8 weeks. | Stroop task measures response inhibition or response interference control. Participants will be shown a series of word colors that are either congruent or incongruent with the color of the word itself. The participant will be asked to respond to the color of the word and not the word itself. Responses are made with the keyboard. The incongruent condition is the more difficult condition of the two. Reaction time is recorded and a cost score is calculated, with shorter cost scores indicating better performance. | ClinicalTrials.gov |
| Primary | Penn Conditional Exclusion Test | From enrollment to end of treatment at 8 weeks. | Neurocognition measure of reasoning \& problem solving in PennCNB. Scores will be transformed into z-scores. The key score will assess perseverative errors. Lowest score = 0, no max score. A higher score is correlated with worse performance, i.e. more perseverative errors. | ClinicalTrials.gov |
| Primary | Flanker Inhibitory Control and Attention Test | From enrollment to end of treatment at 8 weeks. | This test is designed to evaluate an individual's ability to concentrate their attention while inhibiting automatic response tendencies that could potentially hinder goal achievement. This is the percent correct outcome from this assessment. | ClinicalTrials.gov |
| Primary | Face Name Associated Memory Exam | From enrollment to end of treatment at 8 weeks. | The score ranges from 0 to 130, with a higher score indicating better speed of processing. | ClinicalTrials.gov |
| Primary | 9-hole pegboard dexterity test | From enrollment to end of treatment at 8 weeks. | The Nine-Hole Peg Test (9HPT) is used to measure finger dexterity in patients with various neurological diagnoses. Time to complete the test as quickly as possible | ClinicalTrials.gov |
| Primary | NIH Toolbox Cognitive Battery | From enrollment to end of treatment at 8 weeks. | The Nine-Hole Peg Test (9HPT) is used to measure finger dexterity in patients with various neurological diagnoses. Time to complete the test as quickly as possible | ClinicalTrials.gov |
| Primary | Neurite Orientation Dispersion and Density Imaging (NODDI) | From enrollment to end of treatment at 8 weeks. | Assessing synaptic plasticity in MRI | ClinicalTrials.gov |
| Secondary | Complex Working Memory Span task | From enrollment to end of treatment at 8 weeks. | Measures ability to juggle holding information (storage) and doing something with it (processing) at the same time. Percent accuracy will be reported. | ClinicalTrials.gov |
| Secondary | fMRI | From enrollment to end of treatment at 8 weeks. | Mean BOLD signal | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)